Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) reported Q4 EPS of ($0.59), $0.14 worse than the analyst estimate of ($0.45). Revenue for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE